AstraZeneca ties up with Rajiv Gandhi Cancer Institute to treat patients with Chronic Lymphocytic Leukemia

Rajiv Gandhi Cancer Institute (RGCI), Delhi one of Asia’s premier institutes becomes the first strategic partner to adopt and implement Project Chariot in patients across North India & Delhi NCR region

BeOne Medicines wins first-in-world nod for Sonrotoclax in China

The approval is backed by data showing deep, durable responses and manageable tolerability

Lilly drug cuts risk of disease progression or death by 80% in trial

The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study

FDA expands nod of Eli Lilly’s Jaypirca for earlier CLL/SLL treatment

Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor

Imugene reports strong early results for Azer-cel in aggressive blood cancer trial

Eli Lilly to spotlight groundbreaking BTK inhibitor Jaypirca at ASH 2025

Jaypirca is making waves in the fight against B-cell malignancies

AbbVie submits for FDA approval of Venclexta and Acalabrutinib combination for untreated CLL patients

The submission is supported by positive results from the Phase 3 AMPLIFY trial

Glenmark Pharmaceuticals to launch DCGI-approved BRUKINSA in India for treatment of hematological malignancies

Globally, BRUKINSA is approved in more than 70 countries

AbbVie announces emotional impact report on mental health of underrepresented CLL cancer patients

CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US

Merck to acquire investigational B-Cell depletion therapy from Curon Biopharmaceutical

CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases